Please use this identifier to cite or link to this item:
Title: Fixed dose drug combinations - are they pharmacoeconomically sound? : findings and implications especially for lower- and middle-income countries.
Authors: Godman, Brian
McCabe, Holly
Leong, Trudy D.
Mueller, Debjani
Martin, Antony P.
Hoxha, Iris
Mwita, Julius C.
Rwegerera, Godfrey Mutashambara
Massele, Amos
Costa, Juliana de Oliveira
Nascimento, Renata Cristina Rezende Macedo do
Lemos, Livia Lovato Pires de
Tachkov, Konstantin
Milushewa, Petya
Patrick, Okwen
Niba, Loveline Lum
Laius, Ott
Sefah, Israel
Abdulsalim, Suhaj
Soleymani, Fatemeh
Guantai, Anastasia N.
Achieng, Loice
Oluka, Margaret
Jakupi, Arianit
Logvissee, Konstantīns
Hassali, Mohamed Azmi
Kibuule, Dan
Kalemeera, Francis
Mubita, Mwangana
Fadare, Joseph
Ogunleye, Olayinka O.
Saleem, Zikria
Hussain, Shazhad
Bochenek, Tomasz
Mardare, Ileana
Alrasheedy, Alian A.
Furst, Jurij
Tomek, Dominik
Pekovic, Vanda Markovic
Rampamba, Enos M.
Alfadl, Abubakr
Amuuu, Adefolarin A.
Matsebula, Zinhle
Phuong, Thuy Nguyen Thi
Thanh, Binh Nguyen
Kalungia, Aubrey Chichonyi
Zaranyika, Trust
Masuka, Nyasha
Olaru, Ioana D.
Waleccc, Janney
Hill, Ruaraidh
Kurdi, Amanj
Timoney, Angela
Campbell, Stephen
Meyer, Johanna C.
Keywords: Adherence
Non communicable diseases
Infectious diseases
Issue Date: 2020
Citation: GODMAN, B. et al. Fixed dose drug combinations - are they pharmacoeconomically sound?: findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research, v. 20, n. 1, 2020. Disponível em: <>. Acesso em: 10 jun. 2021.
Abstract: Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.
ISSN: 1744-8379
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
5,62 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.